Kura Oncology (KURA) Projected to Release Earnings on Thursday

Kura Oncology (NASDAQ:KURA) is projected to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.8773) per share and revenue of $20.1630 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 12:30 PM ET.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.05. The company had revenue of $18.27 million during the quarter, compared to analysts’ expectations of $25.97 million. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. On average, analysts expect Kura Oncology to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Kura Oncology Stock Up 3.0%

NASDAQ:KURA opened at $9.47 on Wednesday. The company has a market cap of $840.65 million, a PE ratio of -2.83 and a beta of 0.38. Kura Oncology has a twelve month low of $5.45 and a twelve month high of $12.49. The company has a current ratio of 6.15, a quick ratio of 6.14 and a debt-to-equity ratio of 0.09. The company’s 50 day moving average is $10.13 and its two-hundred day moving average is $9.27.

Insider Activity at Kura Oncology

In other news, insider Mollie Leoni sold 84,929 shares of the stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total value of $834,002.78. Following the sale, the insider owned 182,345 shares in the company, valued at $1,790,627.90. This represents a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its position in Kura Oncology by 7.6% during the 4th quarter. Royal Bank of Canada now owns 19,577 shares of the company’s stock worth $203,000 after purchasing an additional 1,375 shares during the period. Focus Partners Advisor Solutions LLC lifted its holdings in shares of Kura Oncology by 7.9% in the 4th quarter. Focus Partners Advisor Solutions LLC now owns 22,889 shares of the company’s stock valued at $238,000 after buying an additional 1,682 shares during the period. Deutsche Bank AG boosted its stake in shares of Kura Oncology by 3.5% in the fourth quarter. Deutsche Bank AG now owns 80,809 shares of the company’s stock worth $840,000 after buying an additional 2,768 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Kura Oncology by 10.9% during the second quarter. The Manufacturers Life Insurance Company now owns 30,273 shares of the company’s stock worth $175,000 after acquiring an additional 2,976 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Kura Oncology by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock worth $333,000 after acquiring an additional 2,977 shares during the period.

Analysts Set New Price Targets

KURA has been the subject of several research reports. CLSA set a $24.00 price objective on shares of Kura Oncology in a research note on Thursday, June 4th. Wall Street Zen upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Sanford C. Bernstein set a $24.00 target price on Kura Oncology in a research note on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research report on Friday, July 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research note on Thursday, June 4th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Kura Oncology presently has an average rating of “Moderate Buy” and a consensus price target of $25.46.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.